Companies › Supernus Pharmaceuticals
4 active drug programs in 6 registered trials: 3 Phase 2, 1 Phase 4, 1 Phase 3, 1 Phase 1; Psychiatry, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Viloxazine Hydrochloride (SPN-812) Norepinephrine transporter inhibitor | SLC6A2 | Phase 4 | Attention-Deficit/Hyperactivity Disorder | Jan 2028 |
| SPN-821 selective, direct enhancer of mTORC1 cellular signaling | MTOR | Phase 2 | Major Depressive Disorder (MDD) | Dec 2026 |
| Huperzine A (SPN-817) Acetylcholinesterase inhibitor | ACHE | Phase 2 | Focal Onset Seizures; Epilepsy | Aug 2027 |
| BIS-001-ER acetylcholinesterase inhibitor | ACHE | Phase 1 | Focal Impaired Awareness Seizures | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02736656 | Viloxazine Hydrochloride (SPN-812) | Phase 3 | Attention-Deficit/Hyperactivity Disorder | Psychiatry | Sep 2026 |
| NCT03474770 | BIS-001-ER | Phase 1 | Focal Impaired Awareness Seizures | Neurology | Dec 2026 |
| NCT07226661 | SPN-821 | Phase 2 | Major Depressive Disorder (MDD) | Psychiatry | Dec 2026 |
| NCT06798896 | Huperzine A (SPN-817) | Phase 2 | Focal Onset Seizures | Neurology | Aug 2027 |
| NCT05518578 | Huperzine A (SPN-817) | Phase 2 | Epilepsy | Neurology | Dec 2027 |
| NCT04781140 | Viloxazine Hydrochloride (SPN-812) | Phase 4 | Attention-Deficit/Hyperactivity Disorder | Psychiatry | Jan 2028 |
Cash of $176m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Alkermes Neurocrine Biosciences Noema Pharma Reunion Neuroscience TrueBinding
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.